Bristol-Myers Squibb Pharmaceutical Research Institute
Conference on Harmonization; Choice of Control Group in Clinical Trials. Bristol-Myers Squibb offers the following comments on the draft guidance: International controlled studies to assess relative risk/benefit. ... Return Document
Cortex Pharmaceuticals - Wikipedia, The Free Encyclopedia
March 2008 – German regulators approved clinical studies for using CX717 to prevent breathing problems caused by opiate pain-killers. Bristol-Myers Squibb; CancerVax; Century Pharmaceuticals; Cephalon; Ceragenix Pharmaceuticals; Combe Incorporated; Cortex Pharmaceuticals; CoTherix; ... Read Article
Bristol-Myers’ Melanoma Immunotherapy Expected To Take The ...
Bristol-Myers Squibb’s (NYSE:BMY) Clinical Oncology (ASCO) on Sunday, June 6. Ipilimumab, an immunotherapy, targets a molecule Results presented last year at ASCO from three Phase II studies showed a two-year survival rate ... Retrieve Content
-more-
Clinical collaboration agreement to conduct a proof-of-concept study of ARISTOTLE and AVERROES studies. On September 21, 2012, Bristol-Myers Squibb and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) ... View Full Source
BMS-562086 (pexacerfont) Bristol-Myers Squibb
In the Phase 2 clinical studies, pexacerfont was dosed at 100 mg/day in approximately 210 subjects for up to 8 weeks in female subjects. The most common treatment-emergent AEs in the Phase 2 studies were headache, Bristol-Myers Squibb BMS-562086, ... Return Document
Buspirone - Wikipedia, The Free Encyclopedia
Clinical depression augmentation agent alongside studies have shown buspirone to be an effective augmentation agent alongside treatment with SSRIs for clinical depression Bristol-Myers Squibb applied for a patent on Oct 28, 1993 and received the patent on Jul 11, 1995 for an ... Read Article
Bristol-Meyes Squibb Collaborative Research Agreement
BRISTOL-MYERS SQUIBB COMPANY of collaborative preclinical and clinical research studies in the area of identification and testing of new disease indications for existing COMPANY drug candidates. ... Read Content
J~lk SquibbO Bristol-Myers
Bristol-Myers SquibbO U'--Pharmaceutical Research Institute P.o. Box 4000 Princeton, NJ 08543-4000 609252-4000;r.}:":c£ OF GENf.b4! of one or more clinical studies at such Institution under specific protocols involving BMS investigational ... View Document
BMS-564,929 - Wikipedia, The Free Encyclopedia
This means there is a clinical need for selective androgen receptor modulators, and in studies on castrated rats it was shown to counteract decrease in muscle mass over time, and at higher doses even increased muscle Bristol-Myers Squibb; Pyrroloimidazoles; Alcohols; Lactams; Imides; Ureas; Nitriles; ... Read Article
BRISTOL-MYERS SQUIBB COMPANY BIOETHICS POLICY STATEMENT ...
BRISTOL-MYERS SQUIBB COMPANY BIOETHICS POLICY STATEMENT (Policy Excerpts) For clinical studies that include a control group, the standard of care provided to the control group(s) should be, at a minimum, equivalent to established and commonly employed treatments ... Fetch Full Source
Portola Initiates Phase 2 Study Of PRT4445, Universal Antidote For Factor Xa Inhibitor Anticoagulants
Portola Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 study evaluating the safety and effectiveness of PRT4445, its universal antidote for Factor Xa inhibitor anticoagulants, in ... Read News
Bristol-Myers Squibb Discovery & Exploratory Clinical Research
Our goal is to discover drugs and conduct early stage clinical studies to show the value of those drugs, evaluate their safety and determine how they work. Bristol-Myers Squibb, we can effect a much bigger impact on the world of patient care than we ... Retrieve Here
Bristol-Myers Squibb Pharmaceutical Research Institute
Bristol-Myers Squibb Pharmaceutical Research Institute PO Box 4000 Prmccton,NJ 05543-4000 Tel It should be clarified whether or not the clinical hold applies to IND studies only, Phase I-III, Phase IV, medical device studies, ... Visit Document
LDL Cholesterol - The Lower The Better? - The Heart Disease ...
In terms of clinical outcome, This study, like most studies involving statin drugs, was sponsored by a drug company. the sponsor was Bristol-Myers Squibb, the makers of pravastatin - not Pfizer, the makers of atorvastatin. ... Read Article
Lessons From Portfolio Management In The Pharmaceutical Industry
The Pfizer alliance with Bristol Myers Squibb to develop the factor Xa inhibitor apixaban is a good example of this [for the treatment of venous thromboembolism]. countries (primarily the running of large clinical studies on thousands of patients), the ... Document Viewer
Bristol-Myers Squibb Pharmaceuticals Ltd Taxol Early Breast ...
Bristol-Myers Squibb Pharmaceuticals Ltd Taxol Early Breast Cancer practice of the rates of neutropenia reported in clinical studies for patients with operable early breast cancer, and of the apparently likely superiority of weekly ... Retrieve Doc
Saladax Biomedical Enters Into Master Collaboration Agreement ...
Include multiple feasibility studies and companion diagnostic development projects. With we’re eager to continue marrying the scientific and clinical knowledge of Bristol-Myers Squibb and Saladax to improve the lives of patients in other clinical areas.” ... Access Doc
Concept Summary Form Clinical Research Proposal
List references, studies, © 2009 Bristol-Myers Squibb Your use of form is subject to the terms of our Privacy Policy. Title: Concept Summary Form Clinical Research Proposal Author: Fittonli Last modified by: patelrk Created Date: 1/20/2010 9:48:00 PM ... Fetch Here
Abilify Study Flawed, Say Researchers - Is Long-Term Use ...
Now Harvard University researchers say that the 2005 approval was based on a single clinical study that had A spokesman for Bristol-Meyers Squibb said that there are other unpublished studies demonstrating the long Bristol Myers Squibb knows that Abilify is not a ... Read Article
Bristol-Myers Squibb To Acquire Amira Pharmaceuticals
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals Acquisition Marks Bristol-Myers Squibb’s Entrance into Fibrotic Diseases, an Area of High which has completed Phase I clinical studies and is now poised for Phase IIa proof-of-confidence studies ... Read Here
The Future For Treatment Of HCV (Spanish Language) - YouTube
Vice President, Global Development Lead HCV BRISTOL-MYERS SQUIBB The standard of care (SOC) therapy for At least three different classes of HCV small molecule inhibitors have shown promise for development in combination studies. New clinical trials are expected to provide ... View Video
HIV And AIDS-Related Clinical Trials Www.clinicaltrials
Clinical Trials module and resource guide or any of the other Bristol-Myers Squibb is not responsible for the content of these sites. HIV and AIDS-Related Clinical Trials Prepared by studies are either open-label ... Read Full Source
Press Release: Anti-Obesity Drug To Target Thyroid Hormone ...
2001 / STOCKHOLM, Sweden, -- Karo Bio and Bristol-Myers Squibb have jointly discovered a novel anti-obesity drug candidate that targets the thyroid hormone receptor. , BMS has been responsible for all animal studies and will be responsible for clinical development. ... Read Article
Bristol-Myers Squibb And Ambrx Announce Collaboration For ...
Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics potential in preclinical studies, and we believe that Bristol-Myers Squibb has the necessary expertise to Ambrx Inc. is a clinical stage biopharmaceutical company using its broad biologics platform to ... Retrieve Full Source
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause ...
Bristol-Myers Squibb Company and Pfizer Inc. today announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS® over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism in 2,486 patients who had already completed 6 to 12 months of anticoagulation treatment for VTE, including deep vein thrombosis or pulmonary embolism . ... Read News
Thorir Bjornsson - VP Early Devlopment & Clinical ...
Thorir joined Wyeth in 2001 from Bristol-Myers Squibb, where he had been Vice President, Clinical research interests have included early clinical development and clinical pharmacology studies, ranging from First-in-Human studies and Proof-of-Concept studies, ... View Video
TEKMIRA PHARMACEUTICALS CORPORATION
Additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; Bristol-Myers Squibb is conducting the preclinical work to validate the function ... View Full Source
No comments:
Post a Comment